Asthma and lower airway diseaseDissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease
Section snippets
Subject recruitment
Study subjects were a randomly selected subset of Puerto Rico islanders who were recruited as part of the ongoing Genes environments & Admixture in Latino Americans (GALA II) study described elsewhere.9, 10, 11 Of the 100 study subjects who participated in this study, 92 were recontacted from their original GALA II study visit. Asthma was defined by a physician's diagnosis and the presence of 2 or more symptoms of coughing, wheezing, or shortness of breath in the 2 years before enrollment.
Whole-transcriptome gene expression signature of the nasal airway epithelium mirrors the bronchial airway epithelium
We performed whole-transcriptome sequencing of nasal airway epithelial brushings from 10 nonatopic control subjects and 10 atopic asthmatic subjects (Table I). Sequencing resulted in an average of 1.1 × 108 (±4 × 107) reads mapped per subject (see Table E1 in this article's Online Repository at www.jacionline.org). Mapped reads were used to generate fragments per kilobase of transcript per million mapped reads (FPKM) gene expression levels, which revealed 16,148 expressed genes in the healthy
Discussion
Transcriptional profiling of the bronchial airways has shown that TH2 inflammation is present in only approximately 50% of asthmatic subjects, revealing the phenotypic heterogeneity of asthma.3 Bronchial airway gene expression changes are associated with inhaled corticosteroid response2 and clinical characteristics, such as eosinophil levels,21 and have identified candidate genes (eg, CLCA122) that, on further study, have increased understanding of asthma pathogenesis.
However, the widespread
References (24)
- et al.
Altered gene expression profiles in nasal respiratory epithelium reflect stable versus acute childhood asthma
J Allergy Clin Immunol
(2005) - et al.
Factors associated with degree of atopy in Latino children in a nationwide pediatric sample: the Genes-environments and Admixture in Latino Asthmatics (GALA II) study
J Allergy Clin Immunol
(2013) - et al.
Asthma outcomes: biomarkers
J Allergy Clin Immunol
(2012) - et al.
Self-cleavage of human CLCA1 protein by a novel internal metalloprotease domain controls calcium-activated chloride channel activation
J Biol Chem
(2012) - National health interview survey 2004-2011. In: Prevention CfDCa, editor. Hyattsville (MD): National Center for Health...
- et al.
Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids
Proc Natl Acad Sci U S A
(2007) - et al.
T-helper type 2-driven inflammation defines major subphenotypes of asthma
Am J Respir Crit Care Med
(2009) - et al.
Lebrikizumab treatment in adults with asthma
N Engl J Med
(2011) - et al.
Dupilumab in persistent asthma with elevated eosinophil levels
N Engl J Med
(2013) - et al.
The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium
Toxicol Pathol
(2006)
Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium
BMC Genomics
Childhood obesity and asthma control in the GALA II and SAGE II studies
Am J Respir Crit Care Med
Cited by (190)
Infant Bronchiolitis Endotypes and the Risk of Developing Childhood Asthma: Lessons From Cohort Studies
2024, Archivos de BronconeumologiaNasopharyngeal airway long noncoding RNAs of infants with bronchiolitis and subsequent risk of developing childhood asthma
2024, Journal of Allergy and Clinical ImmunologyNasal epithelial gene expression and total IgE in children and adolescents with asthma
2024, Journal of Allergy and Clinical ImmunologyT2-low asthma in school-aged children: unacknowledged and understudied
2023, The Lancet Respiratory MedicineProlonged inflammatory resolution in allergic asthma relates to dysfunctional interactions between neutrophils and airway epithelium
2023, Annals of Allergy, Asthma and Immunology
Supported in part by a UCSF Dissertation Year Fellowship and National Institutes of Health (NIH) training grant T32 GM007175 (to C.R.G.); the NIH (ES015794, AI077439, AI079139, AI061774, HL088133, HL078885, HL104608, HL079055, CA113710, and DK064695), the Sandler Foundation, the American Asthma Foundation, and the National Institute on Minority Health and Health Disparities of the National Institutes of Health (P60MD006902; to E.G.B.); and the Colorado Career Development in Genetics and Genomics of Lung Diseases (K12HL090147) and In-kind research support for AmpliSeq assays (sequencing was received from Life Technologies; to M.A.S.).
Disclosure of potential conflict of interest: C. Eng has received research support from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institutes of Health (NIH). J. M. Galanter has received research support from the NHLBI and NIH. C. R. Gignoux has received research support from the NIH and the American Asthma Foundation and has stock/stock options in 23andMe. R. Kumar has received research support from the NIH. E. G. Burchard has received research support from the NHLBI and NIH. M. A. Seibold has received research support from the Colorado Career NIH Development in Genetics and Genomics of Lung Diseases (K12HL090147), Life Technologies, and Pfizer; served as an advisory board member for Genentech; and has patents planned, pending, or issued from MUC5B Genetic Variant in Pulmonary Fibrosis. The rest of the authors declare that they have no relevant conflicts of interest.